title: Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience.
abstract: OBJECTIVE
  To analyze the oncologic results of intermittent androgen deprivation (IAD) for biochemical recurrence after radical prostatectomy (RP).
  
  
  METHODS
  A total of 57 patients with biochemical recurrence after RP have been treated with IAD at our institution. The 57 patients were divided into two groups: group 1 comprised 29 patients who received salvage radiotherapy after RP; group 2 comprised 28 patients who did not receive salvage radiotherapy. Hormonal therapy during the first treatment phase consisted of an antiandrogen alone. This treatment was maintained for 3 months after the prostate-specific antigen (PSA) level had become undetectable and was then discontinued. Hormonal therapy was resumed when the PSA level exceeded 4 ng/mL; treatment was discontinued when the PSA level dropped to less than 1 ng/mL.
  
  
  RESULTS
  The patients in group 1 had less favorable characteristics than those in group 2 in terms of pathologic stage and Gleason score. Overall, the median follow-up after starting hormonal therapy was 92 months (range 36 to 176). The percentage of each cycle that was spent "off" treatment decreased from 60% to 50%. During follow-up, 38.6% of patients required a luteinizing hormone-releasing hormone analog for nonresponse to the antiandrogen alone, and 15.8% experienced metastatic progression. The cancer-specific mortality rate was 12.3%; all patients who died of prostate cancer were from group 1. The median interval between initiation of hormonal therapy and cancer-related death was 86 months.
  
  
  CONCLUSIONS
  In our experience, IAD for biochemical recurrence after RP provided satisfactory long-term oncologic results. Our data suggest that IAD can be initiated with an antiandrogen alone.
authors.affiliation: Department of Urology, Cochin Hospital, Paris, France. michael.peyromaure@cch.ap-hop-paris.fr
authors.forename: Michaël
authors.initials: M
authors.lastname: Peyromaure
authors.forename: Nicolas Barry
authors.initials: NB
authors.lastname: Delongchamps
authors.forename: Bernard
authors.initials: B
authors.lastname: Debré
authors.forename: Marc
authors.initials: M
authors.lastname: Zerbib
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000008:administration & dosage*; D017373:Cyproterone Acetate / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D048289:Imidazolidines / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000517:prevention & control* / Q000601:surgery*; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D048289:Imidazolidines; D017373:Cyproterone Acetate; C021277:nilutamide